Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 7/20 | 0.86 |
| ▸ | DRD3 | P35462 | 2/20 | 0.86 |
| ▸ | DRD2 | P14416 | 5/20 | 0.78 |
| ▸ | HTR1A | P08908 | 2/20 | 0.78 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284189 | 0.93 | DRD1 (1.00) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL12287106 | 0.93 | DRD1 (1.00) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL15170528 | 0.92 | DRD1 (0.91) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL15170601 | 0.92 | DRD1 (0.80) | DRD1DRD3DRD2HTR1A | |
| SCHEMBL15169930 | 0.90 | DRD1 (0.83) | DRD1DRD3DRD2HTR1A | |
| SCHEMBL15170348 | 0.89 | DRD1 (0.86) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL1204032 | 0.88 | DRD1 (1.00) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL1204517 | 0.88 | DRD1 (1.00) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL15170446 | 0.88 | DRD1 (0.87) | DRD1DRD3DRD2HTR1AHTR2A | |
| SCHEMBL15170389 | 0.87 | DRD1 (0.86) | DRD1DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166531-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION | 2017-06-15 | — | — | US | claimed |
| US-20130209362-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-08-15 | — | — | US | claimed |
| US-10081600-B2 | 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170166531-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-9517279-B2 | 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20130209362-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2011130530-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081600-B2 | 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof | HTR5A, HTR2C, HTR3A | DRD1 25/4885DRD3 32/4885DRD2 11/4885 |
| US-20130209362-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | HTR5A, HTR2C, HTR3A | DRD1 25/4885DRD3 32/4885DRD2 11/4885 |
| US-20170166531-A1 | 2-ALKOXY-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | HTR5A, HTR2C, HTR3A | DRD1 25/4885DRD3 32/4885DRD2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.